ALKERMES | ALKS - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
AbbVie USD -5.94B 721M 2026-06
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Amgen USD 11.69B 2.5B 2026-06
Biogen USD 18.85B 196.3M 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Coherus Biosciences USD 60.84M 17.78M 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Gilead Sciences USD 11.74B 11.77B 2026-06
Heron Therapeutics USD 6.91M 2.23M 2026-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
J&J USD 84.97B 3.78B 2026-06
Malin Corporation EUR 193.2M 75M 2024-12
Merck USD 41.93B 3.94B 2026-06
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Nektar Therapeutics USD 576.22M 486.38M 2026-03
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Otsuka Holdings JPY 3.24T 131.63B 2026-06
Ovoca Bio EUR 780K 485K 2025-12
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Vertex Pharmaceuticals USD 20.25B 886M 2026-06